Glaukos(GKOS) Stock Price Today | Quotes & News

US Stock MarketDetailed Quotes

GKOS Glaukos

Watchlist

93.830
+0.020+0.02%

Close Apr 29 16:00 ET

94.900
+1.070+1.14%

Post 20:01 ET

5.36BMarket Cap-33.87P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Wells Fargo Reaffirms Their Buy Rating on Glaukos (GKOS)
TipRanksApr 29 05:36 ET · Ratings
Earnings Preview: Glaukos to Report Financial Results Post-market on April 30
Moomoo NewsApr 24 21:00 ET
Gentuity Expands Executive Leadership Team to Drive Next Phase of Growth and Innovation
PR NewswireApr 22 10:00 ET
Mizuho Securities Maintains Glaukos(GKOS.US) With Buy Rating, Cuts Target Price to $175
Moomoo NewsApr 17 04:32 ET · Ratings
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Cuts Target Price to $140
Moomoo NewsApr 17 04:32 ET · Ratings
Forecasting The Future: 7 Analyst Projections For Glaukos
BenzingaApr 16 18:01 ET

Comments

Teddy123

Mar 11 19:13

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

$Glaukos (GKOS.US)$
Glaukos Unveils Game-Changing Vision Diagnostic Wearable: First-Ever Platform for Glaucoma Testing

Teddy123

Feb 24 20:16

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa

$Glaukos (GKOS.US)$
Revolutionary Eye Treatment Advances: Can Glaukos Transform Keratoconus Care Without Surgery?

Moomoo AI

Jan 21, 2024 22:51

Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.

Investors Bid Glaukos (NYSE:GKOS) up US$137m Despite Increasing Losses YoY, Taking One-year Return to 88%

Meltyy

Dec 19, 2023 15:33

PDUFA Update…

Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...